Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Opus Genetics logo — Gene therapy company for inherited retinal diseases

Opus Genetics

Gene therapy company for inherited retinal diseases

Founded 2021 United States Raleigh, United States 42 employees Grant Total: $20.70M Health Care, Health and Wellness

General Information

Company Name Opus Genetics
Founded Year 2021
Location United States Raleigh, United States
Founders / Decision Makers
Team member
Employees 42
Industries Health Care, Health and Wellness
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Opus Genetics. To contact Opus Genetics, visit opusgtx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Opus Genetics compare?

A PDF of Opus Genetics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Opus Genetics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Opus Genetics

Opus Genetics is a pioneering clinical-stage gene therapy company focused on orphan inherited retinal diseases, aiming to put patients at the forefront of their mission. Established in 2004, the company operates in the Health Care industry and is headquartered in the United States. Opus Genetics has recently received a significant boost with a $1.70M grant investment from the Foundation Fighting Blindness's venture arm, the RD Fund, as of 13 June 2024. Opus Genetics stands out with its distinctive approach and purpose, backed by the influential Foundation Fighting Blindness. Their commitment to addressing patient needs is commendable, as evidenced by their wholly owned programs in various inherited retinal diseases. With unparalleled insight and a solid investment backing, Opus Genetics is positioning itself as a key player in the gene therapy landscape, offering hope to those affected by these challenging conditions. This innovative gene therapy company is a promising prospect for venture capitalists seeking to support impactful solutions in the healthcare sector. It combines a compelling purpose with a robust business model, making it an attractive investment opportunity for those who prioritize social impact and innovation in their investment portfolio. Opus Genetics has the potential to be a game-changer in the gene therapy space and presents a compelling case for investment consideration.

Business keywords: gene therapy, inherited retinal diseases, clinical-stage, patient-first approach, opthamology, start-up, investor-backed, Foundation Fighting Blindness, RD Fund, orphan diseases

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $1.70M 1
Foundation Fighting Blindness
Foundation Fighting Blindness
13 Jun 2024
Seed Round $19.00M 3
Bios Partners the Manning Family Foundation Retinal Degeneration Fund
Bios Partners, the Manning Family Foundation +1
22 Sep 2021

Opus Genetics Alternatives & Competitors

View All Alternatives
Opus Genetics vs
Atsena Therapeutics
Atsena Therapeutics

Clinical-stage gene therapy company developing treatments to reverse/prevent blindness from inherite...

Series C
46 employees
Biotechnology, Health Care
Compare Opus Genetics vs Atsena Therapeutics
Opus Genetics vs
Beacon Therapeutics
Beacon Therapeutics United Kingdom

Transforming Vision, Transforming Lives

Series C
95 employees
Biotechnology, Health Care
Compare Opus Genetics vs Beacon Therapeutics
Opus Genetics vs
AAVantgarde
AAVantgarde

Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease

Series A
70 employees
Biotechnology, Health Care
View all alternatives

FAQ About Opus Genetics

Gene therapy company for inherited retinal diseases
Opus Genetics was founded in 2021.
Opus Genetics is headquartered in Raleigh, United States.
Opus Genetics operates in Health Care and Health and Wellness. Its work centres on gene therapy, inherited retinal diseases, clinical-stage and patient-first approach.
Opus Genetics has approximately 42 employees.
Opus Genetics has completed 2 funding rounds, raising a total of $20.70M. The latest funding stage is Grant.
Top alternatives and competitors to Opus Genetics include Atsena Therapeutics, Beacon Therapeutics, AAVantgarde, Ray Therapeutics, Inc., MeiraGTx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Opus Genetics and Atsena Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Opus Genetics, https://bouncewatch.com/company/opus-genetics, updated 27 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes